| Hazard Information | Back Directory | [Description]
Secukinumab is currently the first and only fully humanized biological agent that can specifically inhibit interleukin 17A (IL-17A). IL-17A is a core pathogenic factor involved in inflammation and disease progression in psoriasis (PsO), psoriasis arthropathy (PsA) and ankylosing spondylitis (AS), and plays a cornerstone role in the pathogenesis. | [Uses]
Secukinumab is a human interleukin-IL-17A antagonist indicated for the treatment of adults with moderate to severe plaque psoriasis as an alternative to systemic therapy or phototherapy. | [Side effects]
The most common adverse reactions (>1%) with secukinumab were nasopharyngitis, diarrhea, and upper respiratory tract infection. |
|
|